Integrated Quantitative Investments LLC Purchases New Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Integrated Quantitative Investments LLC acquired a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 9,900 shares of the medical instruments supplier's stock, valued at approximately $912,000.

Several other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its stake in shares of LeMaitre Vascular by 6.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier's stock worth $17,789,000 after acquiring an additional 11,395 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of LeMaitre Vascular by 7.7% during the third quarter. The Manufacturers Life Insurance Company now owns 11,273 shares of the medical instruments supplier's stock worth $1,047,000 after purchasing an additional 804 shares during the last quarter. FMR LLC boosted its stake in shares of LeMaitre Vascular by 330.6% during the third quarter. FMR LLC now owns 10,568 shares of the medical instruments supplier's stock valued at $982,000 after purchasing an additional 8,114 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of LeMaitre Vascular by 80.7% during the third quarter. BNP Paribas Financial Markets now owns 27,829 shares of the medical instruments supplier's stock valued at $2,585,000 after purchasing an additional 12,432 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in LeMaitre Vascular by 98.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,129 shares of the medical instruments supplier's stock worth $569,000 after buying an additional 3,036 shares during the period. Institutional investors own 84.64% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several equities research analysts have issued reports on LMAT shares. Lake Street Capital boosted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price objective on the stock. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, StockNews.com downgraded LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Five equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, LeMaitre Vascular has an average rating of "Moderate Buy" and an average target price of $95.25.

LeMaitre Vascular Stock Up 2.2 %

Shares of LMAT traded up $1.69 during mid-day trading on Wednesday, hitting $79.58. 142,204 shares of the company traded hands, compared to its average volume of 157,743. The company has a market capitalization of $1.80 billion, a PE ratio of 43.87, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89. The business has a 50 day moving average of $90.33 and a 200 day moving average of $93.95. LeMaitre Vascular, Inc. has a 1-year low of $62.39 and a 1-year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million during the quarter, compared to analysts' expectations of $55.99 million. As a group, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were given a $0.20 dividend. The ex-dividend date was Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a yield of 1.01%. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's dividend payout ratio is currently 41.24%.

Insider Buying and Selling

In other news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now directly owns 5,564 shares of the company's stock, valued at $456,915.68. This represents a 26.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.79% of the stock is owned by corporate insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.